IHD
MCID: ISC006
MIFTS: 68

Ischemic Heart Disease (IHD) malady

Categories: Cardiovascular diseases

Aliases & Classifications for Ischemic Heart Disease

Aliases & Descriptions for Ischemic Heart Disease:

Name: Ischemic Heart Disease 38
Coronary Arteriosclerosis 69
Myocardial Ischemia 69
Ihd 45

Classifications:



External Ids:

ICD10 33 I20-I25

Summaries for Ischemic Heart Disease

MalaCards based summary : Ischemic Heart Disease, also known as coronary arteriosclerosis, is related to lupus erythematosus and systolic heart failure, and has symptoms including angina pectoris and other and unspecified angina pectoris. An important gene associated with Ischemic Heart Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Lipoprotein metabolism. The drugs Olmesartan and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Related Diseases for Ischemic Heart Disease

Diseases related to Ischemic Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
id Related Disease Score Top Affiliating Genes
1 lupus erythematosus 29.6 ACE CRP IL6
2 systolic heart failure 29.4 ACE AGTR1 CRP
3 myocardial infarction 28.1 ACE AGTR1 APOA1 APOB APOE CRP
4 coronary artery disease 11.1
5 kawasaki disease 11.1
6 heart disease 11.1
7 sick sinus syndrome 10.8
8 lupus erythematosus panniculitis 10.3 ACE APOE
9 alport syndrome and thin basement membrane nephropathy 10.3 APOE LPL
10 zap-70 deficiency 10.3 APOB APOE
11 keratoconus 4 10.3 APOB APOE
12 mechanical entropion 10.3 APOE NOS3
13 kartagener syndrome 10.3 ACE NOS3
14 iron metabolism disease 10.3 ACE APOE CRP
15 familial progressive cardiac conduction defect 10.3 APOA1 APOE
16 coloboma of iris 10.2 CRP IL6
17 severe hemophilia a 10.2 ACE TNF
18 acute infection of pinna 10.2 CRP INS
19 asphyxia neonatorum 10.2 ACE APOE LPL
20 dentinogenesis imperfecta type 2 10.2 APOB APOE
21 villous adenoma 10.2 ACE CRP NOS3
22 severe intellectual disability-progressive postnatal microcephaly- midline stereotypic hand movements syndrome 10.2 APOB APOE LPL
23 cardiac sarcoidosis 10.2 ACE TNF
24 pars planitis 10.2 ACE APOA1 APOE
25 dermatosis papulosa nigra 10.2 ACE TNF
26 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
27 hyperchlorhidrosis, isolated 10.2 APOA1 APOE LPL
28 albinism, oculocutaneous, type v 10.2 APOA1 APOB APOE
29 cutaneous sclerosis 10.2 CRP IL6
30 secretory diarrhea myopathy and deafness 10.2 ACE CRP IL6
31 stone in bladder diverticulum 10.2 APOA1 APOB APOE
32 ischemic optic neuropathy 10.2 ACE CRP IL6
33 dyslexia 5 10.2 IL6 TNF
34 neuropathy, hereditary sensory and autonomic, type ia 10.2 APOA1 APOB APOE
35 shoulder impingement syndrome 10.2 CRP IL6
36 anogenital venereal wart 10.1 ACE CRP TNF
37 aortic atherosclerosis 10.1 IL6 TNF
38 deafness, autosomal recessive 79 10.1 ACE CRP NPPB
39 degenerative disc disease 10.1 IL6 TNF
40 familial periodic paralysis 10.1 ACE CRP NPPB
41 c1s deficiency 10.1 APOE INS LPL
42 endotheliitis 10.1
43 swine influenza 10.1 CRP IL6 TNF
44 human immunodeficiency virus infectious disease 10.1 CRP IL6 TNF
45 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.1 ACE CRP NPPB
46 cicatricial lagophthalmos 10.1 CRP IL6 TNF
47 benign neonatal seizures 10.1 CRP IL6 TNF
48 inferolateral myocardial infarct 10.1 ACE NPPB
49 neuropathy 10.1 CRP IL6 TNF
50 autoimmune disease of central nervous system 10.1 CRP IL6 TNF

Comorbidity relations with Ischemic Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 199)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Anterolateral Myocardial Infarction Acute Apical Periodontitis
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Myocarditis
Acute Pancreatitis Acute Stress Disorder
Adjustment Disorder Alcoholic Cardiomyopathy
Allergic Urticaria Anthracosis
Anxiety Disorder Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 2
Aortic Valve Insufficiency Aplastic Anemia
Asbestosis Atrioventricular Block
Atrophic Gastritis Atypical Depressive Disorder
Autonomic Nervous System Disease Bacteremia
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Paroxysmal Positional Nystagmus
Benign Renovascular Hypertension Bicipital Tenosynovitis
Bleeding Disorder, Platelet-Type, 11 Blepharoconjunctivitis
Bronchitis Bronchopneumonia
Buerger Disease Cardiac Arrest
Cardiogenic Shock Cardiomyopathy, Familial Hypertrophic
Central Nervous System Origin Vertigo Central Retinal Artery Occlusion
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Cholecystitis
Chronic Kidney Failure Chronic Myocardial Ischemia

Graphical network of the top 20 diseases related to Ischemic Heart Disease:



Diseases related to Ischemic Heart Disease

Symptoms & Phenotypes for Ischemic Heart Disease

UMLS symptoms related to Ischemic Heart Disease:


angina pectoris, other and unspecified angina pectoris

GenomeRNAi Phenotypes related to Ischemic Heart Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE LPL
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Ischemic Heart Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.26 F7 IL6 INS LPL NOS3 TNF
2 homeostasis/metabolism MP:0005376 10.18 APOE CRP F7 IL6 INS LPL
3 adipose tissue MP:0005375 10.15 ACE AGTR1 APOE F7 IL6 INS
4 growth/size/body region MP:0005378 10.13 ACE AGTR1 APOB APOE F7 IL6
5 immune system MP:0005387 10.02 APOE CRP IL6 INS NOS3 TNF
6 endocrine/exocrine gland MP:0005379 10 ACE APOA1 APOE IL6 INS NOS3
7 liver/biliary system MP:0005370 9.97 ACE APOA1 APOB APOE IL6 INS
8 mortality/aging MP:0010768 9.96 ACE AGTR1 APOB APOE F7 IL6
9 muscle MP:0005369 9.7 APOB APOE IL6 INS LPL NOS3
10 renal/urinary system MP:0005367 9.43 ACE AGTR1 APOE IL6 INS NOS3
11 reproductive system MP:0005389 9.17 TNF ACE APOB APOE IL6 INS

Drugs & Therapeutics for Ischemic Heart Disease

Drugs for Ischemic Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 894)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 158781 130881
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
5
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
6
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 9552079 2713
7
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
8
Tirofiban Approved Phase 4,Phase 3,Phase 1 144494-65-5 60947
9
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
10
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
11
Insulin Glargine Approved Phase 4 160337-95-1
12
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
13
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
14
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
15
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
16
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-78-2 2244
17
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
18
Ticagrelor Approved Phase 4,Phase 2,Phase 3,Phase 1 274693-27-5 9871419
19
Warfarin Approved Phase 4,Phase 3 81-81-2 6691 54678486
20
Cilostazol Approved Phase 4,Phase 3,Phase 2 73963-72-1 2754
21
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1 55142-85-3 5472
22
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
23
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 122320-73-4 77999
24
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
25
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
26
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
27
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
28
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
29
Coal tar Approved Phase 4,Phase 1,Phase 2 8007-45-2
30
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-61-7 60961
31
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1 58-32-2 3108
32
Regadenoson Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 313348-27-5 219024
33
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
34
Nicorandil Approved Phase 4 65141-46-0 47528
35
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
36
Pantoprazole Approved Phase 4,Phase 3,Phase 1 102625-70-7 4679
37
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
38
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
39
Eptifibatide Approved, Investigational Phase 4,Phase 3,Phase 2 188627-80-7 123610
40
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
41
Menthol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 2216-51-5 16666
42
Phenprocoumon Approved Phase 4 435-97-2 9908 54680692
43
Esmolol Approved Phase 4,Phase 3,Phase 1,Phase 2 103598-03-4, 81147-92-4 59768
44
Nicardipine Approved Phase 4 55985-32-5 4474
45 Trapidil Approved Phase 4 15421-84-8
46
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
47
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3 249296-44-4 5310966
48
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
49
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
50
Bisoprolol Approved Phase 4,Phase 2,Phase 3,Early Phase 1 66722-44-9 2405

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4
2 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4
3 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4
4 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4
5 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4
6 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4
7 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4
8 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4
9 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4
10 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
11 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4
12 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4
13 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4
14 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4
15 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4
16 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4
17 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
18 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
19 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
20 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4
21 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4
22 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4
23 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4
24 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
25 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4
26 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
27 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
28 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
29 Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Unknown status NCT01342822 Phase 4
30 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4
31 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4
32 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
33 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4
34 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4
35 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
36 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4
37 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
38 Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Unknown status NCT00963781 Phase 4
39 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
40 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
41 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
42 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
43 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
44 Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial Unknown status NCT01810224 Phase 4
45 Atorvastatin Plus Ezetimibe on Coronary Plaque Progression Unknown status NCT01086020 Phase 4
46 Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries Unknown status NCT01903902 Phase 4
47 Effect of Statins on the Radial Intima-media Thickness After Transradial Angioplasty Unknown status NCT00952770 Phase 4
48 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms Unknown status NCT01776567 Phase 4
49 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns Unknown status NCT01024179 Phase 4
50 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4

Search NIH Clinical Center for Ischemic Heart Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ischemic Heart Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Ischemic Heart Disease:
ACT34-CMI, bone marrow-derived cells for ischemic heart diseases
Adipocell
Adipose-derived mesenchymal stromal stem cells for ischemic heart disease
ADRCs, adipose-derived regenerative cells for cardiovascular disease
AMDC, autologous muscle-derived cells for ischemic heart failure
Autologous bone marrow-derived mesenchymal stem cells for treatment of heart muscle damage
Bone marrow-derived CD133+ stem cells for treatment of ischemic heart disease
Bone marrow-derived mesenchymal stem cells for treatment of heart diseases
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy during artery bypass grafting
Bone marrow-derived mesenchymal stem cells for treatment of ischemic heart disease
Bone marrow-derived mononuclear cells for ischemic cardiomyopathy
Bone marrow-derived mononucleated cells for heart disease
Bone marrow-derived stem cells for treatment of chronic ischemic heart failure
Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived stem cells for treatment of severe chronic ischemic heart disease
Cardiac stem cells for treatment of ischemic cardiomyopathy
Cardiocell
Combination therapy of mononuclear cells with laser for coronary disease
Embryonic stem cell-derived cardiomyocytes for ischemic myocardium
Enriched bone marrow-derived progenitor cells for heart diseases
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of cardiovascular diseases
Peripheral mononuclear cells CD34+ stem cells for treatment of myocardial ischemia
Peripheral or bone marrow-derived stem cells for chronic heart failure
StempeucelICM
Embryonic/Adult Cultured Cells Related to Ischemic Heart Disease:
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 11283669 12551872 22163120 20448213 9020076 17562958 21737787
VEGF-A165-stimulated ADSCs
Adipose-derived stem and regenerative cells PMIDs: 21082397 22281257
Autologous muscle-derived cells
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21052537 19591227
Bone marrow-derived CD133+ cells
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Bone marrow-derived hematopoietic stem cells (family)
Bone marrow-derived stem cells
Bone marrow-derived mononuclear cells (family) PMIDs: 21392602 22940024
Porcine bone marrow-derived mesenchymal stem cells PMIDs: 21392602 22940024
Human cardiac stem cells PMIDs: 22088800 22965994
Cardiomyocyte-like cells PMIDs: 18941512
Bone marrow-derived progenitor cells PMIDs: 23362308 22936827 18794392 16990384 16990385 22651868
Bone marrow-derived mononuclear cells PMIDs: 21323410 20631864
Bone marrow-derived mesenchymal stem cells PMIDs: 21323410 20631864
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 20668107 21596713 19761394 22834565
Bone marrow-derived mesenchymal stem cells (Stempeucel PMIDs: 18720444

Genetic Tests for Ischemic Heart Disease

Anatomical Context for Ischemic Heart Disease

MalaCards organs/tissues related to Ischemic Heart Disease:

39
Heart, Bone, Bone Marrow, Endothelial, Testes, Breast, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ischemic Heart Disease:
id Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ischemic Heart Disease

Articles related to Ischemic Heart Disease:

(show top 50) (show all 943)
id Title Authors Year
1
The Effects of Age, Period, and Cohort on Mortality from Ischemic Heart Disease in China. ( 28067846 )
2017
2
Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease. ( 27911047 )
2017
3
Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease: A systematic review and meta-analysis. ( 28383437 )
2017
4
The long-term risk of smoking in diabetic patients with stable ischemic heart disease treated with intensive medical therapy and lifestyle modification. ( 28517955 )
2017
5
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. ( 28067532 )
2017
6
HIV and Ischemic Heart Disease. ( 28057253 )
2017
7
Selective Pressure-Regulated Retroinfusion for Gene Therapy Application in Ischemic Heart Disease. ( 27910055 )
2017
8
Smoking impairs and circulating stem cells favour the protective effect of the T allele of the connexin37 gene in ischemic heart disease--A multinational study. ( 26588185 )
2016
9
Patients with Primary Open-Angle Glaucoma May Develop Ischemic Heart Disease More Often than Those without Glaucoma: An 11-Year Population-Based Cohort Study. ( 27649414 )
2016
10
Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study. ( 27996050 )
2016
11
Spatial Patterns of Ischemic Heart Disease in Shenzhen, China: A Bayesian Multi-Disease Modelling Approach to Inform Health Planning Policies. ( 27104551 )
2016
12
Treatment of Patients With Stable Ischemic Heart Disease--Reply. ( 27139073 )
2016
13
Birth weight and risk of ischemic heart disease: A Mendelian randomization study. ( 27924921 )
2016
14
Factors Associated With Utilization of Cardiac Rehabilitation Among Patients With Ischemic Heart Disease in the Veterans Health Administration: A QUALITATIVE STUDY. ( 27115074 )
2016
15
Hidden in Plain Sight: Lung Impairment in Ischemic Heart Disease. ( 27585376 )
2016
16
Clinical profile and 30-day outcome of women with acute coronary syndrome as a first manifestation of ischemic heart disease: A single-center observational study. ( 27133325 )
2016
17
Erratum: Effectiveness of discharge planning on physical quality of life of patients with ischemic heart disease. ( 27563595 )
2016
18
Coexisting geriatric anxiety and depressive disorders may increase the risk of ischemic heart disease mortality-a nationwide longitudinal cohort study. ( 27966781 )
2016
19
Treatment of Patients With Stable Ischemic Heart Disease--Reply. ( 27139072 )
2016
20
Concomitant CABG, Left Ventricular Restoration and Mitral Valve Repair for Ischemic Heart Disease. ( 28054895 )
2016
21
Helicobacter pylori infection and ischemic heart disease: could experimental data lead clinical studies? ( 27603552 )
2016
22
Impact of chronic ischemic heart disease on the health care costs of COPD patients - An analysis of German claims data. ( 27578479 )
2016
23
Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study. ( 27914500 )
2016
24
Psychosocial Risk Factors Related to Ischemic Heart Disease in Women. ( 27194439 )
2016
25
Intramyocardial Dissecting Hematoma: Cardiac Trauma and Ischemic Heart Disease: Multimodality Imaging Techniques. ( 27112500 )
2016
26
Experiences of peer support in self-management interventions among people with ischemic heart disease: a systematic review protocol. ( 27532134 )
2016
27
Ischemic heart disease and early diagnosis. Study on the predictive value of 2D strain. ( 27111182 )
2016
28
Stable ischemic heart disease in the older adults. ( 27168734 )
2016
29
Signal-Averaged Electrocardiography as a Noninvasive Tool for Evaluating the Outcomes After Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Heart Disease: Reassessment of an Old Tool. ( 27635068 )
2016
30
Prevalence of ischemic heart disease and associated factors in patients with rheumatoid arthritis in Southern Brazil. ( 28089232 )
2016
31
Clinical significance of noninvasive coronary flow reserve assessment in patients with ischemic heart disease. ( 27652814 )
2016
32
Association between Noise Pollution and Prevalent Ischemic Heart Disease. ( 28068283 )
2016
33
Conversion to Purkinje-Related Monomorphic Ventricular Tachycardia After Ablation of Ventricular Fibrillation in Ischemic Heart Disease. ( 27635070 )
2016
34
Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. ( 27059219 )
2016
35
Treatment of Patients With Stable Ischemic Heart Disease. ( 27139069 )
2016
36
Higher circulating levels of chemokines CXCL10, CCL20 and CCL22 in patients with ischemic heart disease. ( 27152707 )
2016
37
The Role of MicroRNA and LncRNA-MicroRNA Interactions in Regulating Ischemic Heart Disease. ( 27635038 )
2016
38
Association of Major Depression With Risk of Ischemic Heart Disease in a Mega-Cohort of Chinese Adults: The China Kadoorie Biobank Study. ( 28003250 )
2016
39
Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. ( 27006480 )
2016
40
Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population. ( 26761769 )
2016
41
Should patients with stable ischemic heart disease undergo revascularization? ( 27505876 )
2016
42
Ischemic heart disease deaths, disability-adjusted life years and risk factors in Fujian, China during 1990-2013: Data from the Global Burden of Disease Study 2013. ( 27077547 )
2016
43
Acid-reducing vagotomy is associated with reduced risk of subsequent ischemic heart disease in complicated peptic ulcer: An Asian population study. ( 27977613 )
2016
44
The relationship between the dietary inflammatory index and risk of total cardiovascular disease, ischemic heart disease and cerebrovascular disease: Findings from an Australian population-based prospective cohort study of women. ( 27498398 )
2016
45
The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona. ( 27169692 )
2016
46
Occupational noise and ischemic heart disease: A systematic review. ( 27569404 )
2016
47
Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guidelineon Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. ( 27601566 )
2016
48
Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. ( 27120522 )
2016
49
The effect of hematocrit and hemoglobin on the risk of ischemic heart disease: A Mendelian randomization study. ( 27609746 )
2016
50
TCT-356 The use of robotic-assisted PCI for the treatment of patients with ischemic heart disease. ( 27969704 )
2016

Variations for Ischemic Heart Disease

ClinVar genetic disease variations for Ischemic Heart Disease:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NOS3 NM_000603.4(NOS3): c.894T> G (p.Asp298Glu) single nucleotide variant risk factor rs1799983 GRCh37 Chromosome 7, 150696111: 150696111

Expression for Ischemic Heart Disease

LifeMap Discovery
Genes differentially expressed in tissues of Ischemic Heart Disease patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Heart + 3.61 0.020
2 LEP leptin Heart + 3.55 0.003
3 MFSD4 major facilitator superfamily domain containing 4 Endothelium + 3.54 0.000
4 FOSB FBJ murine osteosarcoma viral oncogene homolog B Heart + 3.13 0.012
5 DDX3Y DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked Heart + 3.12 0.017
6 RBP4 retinol binding protein 4, plasma Heart + 3.11 0.011
Search GEO for disease gene expression data for Ischemic Heart Disease.

Pathways for Ischemic Heart Disease

Pathways related to Ischemic Heart Disease according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 APOA1 APOB APOE LPL
2
Show member pathways
12.39 APOA1 APOB APOE LPL
3
Show member pathways
12.38 AGTR1 IL6 NOS3 TNF
4
Show member pathways
12.11 APOA1 APOB APOE LPL
5 11.79 IL6 INS LPL TNF
6
Show member pathways
11.73 APOA1 APOB APOE
7 11.7 IL6 INS NOS3
8 11.67 IL6 INS LPL
9
Show member pathways
11.66 IL6 INS NOS3 TNF
10
Show member pathways
11.57 ACE AGTR1 NOS3
11
Show member pathways
11.56 APOA1 APOB APOE CRP F7 IL6
12 11.55 AGTR1 IL6 NOS3 TNF
13 11.31 APOB IL6 TNF
14 11.26 APOE IL6 TNF
15 11.12 APOA1 IL6 TNF
16
Show member pathways
11.09 APOA1 APOB APOE LPL
17 10.61 CRP IL6 TNF

GO Terms for Ischemic Heart Disease

Cellular components related to Ischemic Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.85 APOA1 APOB APOE F7 IL6 INS
2 endocytic vesicle lumen GO:0071682 9.61 APOA1 APOB APOE
3 low-density lipoprotein particle GO:0034362 9.58 APOA1 APOB APOE
4 intermediate-density lipoprotein particle GO:0034363 9.5 APOA1 APOB APOE
5 endosome lumen GO:0031904 9.46 APOB INS
6 very-low-density lipoprotein particle GO:0034361 9.46 APOA1 APOB APOE LPL
7 extracellular space GO:0005615 9.36 ACE APOA1 APOB APOE CRP F7
8 chylomicron GO:0042627 9.26 APOA1 APOB APOE LPL
9 extracellular region GO:0005576 10 ACE APOA1 APOB APOE CRP F7

Biological processes related to Ischemic Heart Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 APOB CRP IL6 INS TNF
2 cellular protein metabolic process GO:0044267 9.92 APOA1 APOB APOE IL6 INS
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.9 IL6 INS TNF
4 lipid transport GO:0006869 9.89 APOA1 APOB APOE
5 steroid metabolic process GO:0008202 9.87 APOA1 APOB APOE
6 cholesterol metabolic process GO:0008203 9.85 APOA1 APOB APOE
7 positive regulation of protein kinase B signaling GO:0051897 9.85 F7 IL6 INS TNF
8 defense response to Gram-positive bacterium GO:0050830 9.83 CRP IL6 TNF
9 regulation of blood pressure GO:0008217 9.83 ACE NOS3 NPPB
10 cholesterol homeostasis GO:0042632 9.78 APOA1 APOB APOE LPL
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 IL6 INS TNF
12 acute-phase response GO:0006953 9.76 CRP IL6 INS
13 retinoid metabolic process GO:0001523 9.76 APOA1 APOB APOE LPL
14 triglyceride homeostasis GO:0070328 9.74 APOA1 APOE LPL
15 cholesterol efflux GO:0033344 9.73 APOA1 APOB APOE
16 positive regulation of nitric-oxide synthase activity GO:0051000 9.72 APOE INS
17 nitric oxide mediated signal transduction GO:0007263 9.72 APOE NOS3
18 reverse cholesterol transport GO:0043691 9.72 APOA1 APOE
19 regulation of blood vessel size GO:0050880 9.72 NOS3 NPPB
20 high-density lipoprotein particle remodeling GO:0034375 9.71 APOA1 APOE
21 negative regulation of lipid catabolic process GO:0050995 9.71 INS TNF
22 regulation of protein secretion GO:0050708 9.71 INS TNF
23 positive regulation of chemokine production GO:0032722 9.71 IL6 TNF
24 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.71 AGTR1 APOB LPL
25 positive regulation of cellular protein metabolic process GO:0032270 9.7 AGTR1 INS
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 APOE TNF
27 negative regulation of gluconeogenesis GO:0045721 9.69 IL6 INS
28 high-density lipoprotein particle assembly GO:0034380 9.69 APOA1 APOE
29 fatty acid homeostasis GO:0055089 9.69 APOE INS
30 regulation of vasodilation GO:0042312 9.69 ACE AGTR1 NPPB
31 phospholipid efflux GO:0033700 9.68 APOA1 APOE
32 positive regulation of lipid biosynthetic process GO:0046889 9.68 APOE INS
33 positive regulation of leukocyte chemotaxis GO:0002690 9.68 F7 IL6
34 neutrophil mediated immunity GO:0002446 9.67 ACE IL6
35 negative regulation of platelet activation GO:0010544 9.67 APOE NOS3
36 high-density lipoprotein particle clearance GO:0034384 9.67 APOA1 APOE
37 low-density lipoprotein particle remodeling GO:0034374 9.67 AGTR1 APOB APOE
38 lipoprotein metabolic process GO:0042157 9.67 APOA1 APOB APOE LPL
39 chylomicron remnant clearance GO:0034382 9.66 APOB APOE
40 very-low-density lipoprotein particle remodeling GO:0034372 9.65 APOE LPL
41 positive regulation of cholesterol storage GO:0010886 9.65 APOB LPL
42 neuron projection regeneration GO:0031102 9.64 APOA1 APOE
43 negative regulation of vasodilation GO:0045908 9.64 CRP INS
44 negative regulation of hydrolase activity GO:0051346 9.63 APOA1 NOS3
45 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.63 ACE AGTR1
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 APOA1 TNF
47 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.62 IL6 TNF
48 very-low-density lipoprotein particle clearance GO:0034447 9.61 APOB APOE
49 regulation of Cdc42 protein signal transduction GO:0032489 9.61 APOA1 APOE
50 lipoprotein biosynthetic process GO:0042158 9.61 APOA1 APOB APOE

Molecular functions related to Ischemic Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.73 F7 IL6 LPL NPPB
2 phospholipid binding GO:0005543 9.58 APOA1 APOB APOE
3 lipoprotein particle binding GO:0071813 9.37 APOA1 APOE
4 lipid transporter activity GO:0005319 9.33 APOA1 APOB APOE
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.32 APOA1 APOE
6 bradykinin receptor binding GO:0031711 9.26 ACE AGTR1
7 cholesterol transporter activity GO:0017127 9.13 APOA1 APOB APOE
8 low-density lipoprotein particle receptor binding GO:0050750 8.8 APOB APOE CRP

Sources for Ischemic Heart Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....